PMV PHARMACEUTICALS, INC. Retained Earnings
PMV PHARMACEUTICALS, INC. (PMVP) had Retained Earnings of -$482.58 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$482.58M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$464.49M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$446.45M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$428.42M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$482.58M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$464.49M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$446.45M 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$428.42M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$407.36M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$386.15M 10-Q · filed 2025-05-09 |
| 2024-12-31 | -$368.71M 10-K · filed 2026-03-06 |
| 2024-09-30 | -$345.71M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$326.49M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$325.27M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$310.00M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$294.25M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$277.61M 10-Q · filed 2023-08-09 |
| 2023-03-31 | -$260.17M 10-Q · filed 2023-05-10 |
| 2022-12-31 | -$241.04M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$221.70M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$203.47M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$186.16M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$167.73M 10-K · filed 2023-03-01 |
| 2021-09-30 | -$149.37M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$134.36M 10-Q · filed 2021-08-13 |
| 2021-03-31 | -$121.48M 10-Q · filed 2021-05-14 |
| 2020-12-31 | -$109.88M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$99.43M 10-Q · filed 2020-11-13 |
| 2019-12-31 | -$75.44M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |